Integrated Silicon Solution, (Nasdaq: ISSI) $7.49. Announced Monday after market close its financial guidance for the second fiscal quarter ending March 31, 2010. During the March quarter to date, the Company has experienced better than expected end market demand and pricing, primarily for its DRAM products.
As a result, the company is increasing its revenue and margin guidance for the quarter. In addition, due to higher than expected new product mask costs and non-executive employee compensation, the Company now expects its operating expenses to be higher than previously expected. The Company also expects its net income and earnings per share to be higher than its prior guidance.
ISSI's updated guidance for the March quarter is as follows:Revenue to be between $54 million and $56 million compared to previous guidance of $48 million to $52 million. Gross margin to be between 34 percent and 38 percent compared to previous guidance of between 28 percent and 32 percent. Operating expenses to be in a range of $14.0 million to $14.6 million compared to previous guidance of $12.4 million to $13.0 million. Net income to be between $0.20 and $0.24 per fully diluted share compared to previous guidance of between $0.08 and $0.12 per share.
What They Do: ISSI is a fabless semiconductor company that designs and markets high performance integrated circuits for the following key markets: Digital consumer electronics, Networking, Mobile communications, Automotive electronics, and Industrial. The Company's primary products are high speed and low power SRAM and low and medium density DRAM.
To read more about Integrated Silicon Solution visit http://www.smallcapreview.com/issi.htm
Dynavax Technologies Corporation (Nasdaq: DVAX) $1.27. Today announced it will present for the first time a detailed analysis of safety data for HEPLISAV, an investigational adult hepatitis B vaccine, including two major findings: The safety profile of HEPLISAV was comparable to that of Engerix-B®, one of two currently licensed vaccines for the prevention of hepatitis B infection, and There is no difference in autoimmune adverse events or laboratory markers of autoimmunity between subjects vaccinated with HEPLISAV and Engerix-B.
The results of nine completed clinical studies comparing HEPLISAV to Engerix-B and an analysis of approximately 9,300 blood samples from subjects vaccinated with HEPLISAV or Engerix-B will be presented at the Drug Information Association's (DIA) Third Oligonucleotides-based Therapeutics Conference in Bethesda, MD on March 24, 2010. The safety data was originally prepared for submission to the FDA as part of extensive documentation that formed the basis upon which HEPLISAV's clinical development was allowed to resume in late 2009.
What They Do: Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases.
Ipsen and GTx, Inc. (Nasdaq: GTXI) $3.59. Today jointly the expansion of their partnership for for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy (ADT) and toremifene 20 mg for the prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN).
Under the terms of the amended collaboration agreement, Ipsen will pay GTx up to 42 million euros (approximately $58 million, based on current exchange rates) in milestone payments upon the initiation, enrollment and progression of the second toremifene 80 mg Phase III clinical trial. In return, GTx has granted Ipsen: The right to co-promote toremifene 80 mg in the United States or, in lieu of co-promoting in the US, the right to a double digit royalty stream on net sales of toremifene 80 mg in the U.S. An expansion of Ipsen’s licensed territory for marketing toremifene products beyond Europe, including Australia and certain countries in North Africa, the Middle East, and Asia (excluding
Relief from Ipsen’s previous contractual obligations, notably to pay GTx potential remaining milestones related to the European approval of toremifene 80 mg. Royalties on Ipsen’s net sales of toremifene 80 mg set at a fixed low teens rate compared to a variable rate previously. A first right of negotiation under certain conditions for rights to GTx-758, currently in Phase II clinical trial for the first-line treatment of men with advanced prostate cancer, in Ipsen’s licensed toremifene territories.
What They Do: GTx, Inc., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to prevent and treat cancer, fractures and bone loss, muscle loss and other serious medical conditions.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
